Alzheimer's Detection · Cain Global Innovations

Section Two

The Diagnostic Gap That Defines Alzheimer’s

Alzheimer’s disease does not begin when a patient walks into a clinic with memory problems. It begins 15 to 20 years earlier, in silence. Amyloid plaques form. Tau tangles spread. Cerebral blood flow patterns shift. Synaptic dysfunction begins. The patient feels fine. The brain is changing.

By the time current standard-of-care diagnostics detect impairment, 15 to 20 years of irreversible neuronal loss has already occurred.

The 15 to 20 Year Window. A timeline showing four stages of Alzheimer's progression from early pathology through clinical diagnosis, with the EchoScan platform operating across the entire pre-symptomatic window.

Section Three

How the Platform Measures the Brain

The EchoScan and BioSignal Bridge platform measures the brain’s biological state through three independent physical principles. Each domain captures different information. Together, they form a complete picture of tissue health that no single measurement could produce alone.

Three Independent Measurement Domains. Acoustic Interrogation, Ultraweak Biological Emissions, and Biological Order Detection, all converging into a unified Fusion Engine.

A natural question follows. The acoustic domain works easily on soft tissue. The brain sits behind the skull. How does the acoustic interrogation actually reach brain tissue?

The skull is a known constraint of any acoustic brain technology. It is not an unsolved problem. Three established clinical and research fields, transcranial Doppler ultrasound, MR-guided focused ultrasound therapy, and functional ultrasound imaging, already deliver acoustic energy across the intact human skull every day. EchoScan inherits this body of work. The platform operates through the same natural acoustic windows used by transcranial Doppler, with phased-array skull correction adapted from established focused-ultrasound practice.

How Acoustic Energy Reaches the Brain. The phased-array transducer at the temporal acoustic window delivers calibrated acoustic energy through the skull. Reflected and absorbed components are minor. The transmitted signal converges on a focal target deep in the brain via per-element timing offsets that correct for skull distortion.

Section Four

One Unified Biological State Index

Three measurement streams converge through the fusion engine into a single clinical readout, the Neural Biological State Index. The example below shows how a patient with subtle pre-symptomatic biological signal is identified during the asymptomatic window with an NBSI of 2.31, classified as a Pre-Clinical Alzheimer’s Pattern.

The Fusion Engine for Alzheimer's. Three sub-scores fuse into a single Neural Biological State Index of 2.31, classified as a Pre-Clinical Alzheimer's Pattern.

Section Five

How the Platform Classifies a Reading

The Neural Biological State Index is interpreted against four clinical zones, from Normal Brain Aging at the bottom of the scale to Established Alzheimer’s Pathology at the top. Each zone carries a clear clinical recommendation. The platform does not produce probabilities or guesses. It produces actionable categories.

NBSI Zone Reference. Four-zone vertical scale from Normal Brain Aging through Established Alzheimer's Pathology, each with a corresponding clinical recommendation.

Section Six

A Snapshot Is Not a Destiny

A single scan tells you where the patient stands today. Repeat scans tell you where they are going. The Trajectory Velocity Score is the second clinical number the platform produces, measuring how fast the patient is progressing along the preclinical-to-symptomatic continuum.

Two patients with the same NBSI today can have radically different futures.

Trajectory Velocity, Beyond the Snapshot. A five-year longitudinal view of NBSI progression with a Trajectory Velocity Score of plus 0.18 per year, crossing the Pre-Clinical Alzheimer's zone boundary.

Two Patients, Same Score, Different Futures. Patient A remains stable while Patient B progresses sharply, despite identical baseline scores.

Section Seven

A Complementary Layer in Alzheimer’s Detection

The platform does not replace existing Alzheimer’s diagnostic tools. It extends them. Cognitive testing measures functional decline after symptoms have begun. Blood biomarkers like plasma pTau217 confirm underlying pathology biochemically.

The EchoScan and BioSignal Bridge platform adds a tissue-level measurement layer that operates earlier in the disease course, captures trajectory over time, and complements every other tool already in clinical use.

The Diagnostic Stack. A four-tier ecosystem from clinical symptoms at the top to tissue-level platform detection at the foundation, extending the diagnostic window backward by 15 to 20 years.

Complementary, Not Competitive. Side-by-side comparison of blood-based biomarkers and the EchoScan platform, each answering a different clinical question.

Section Eight

Routine Screening for Adults Age 50 and Older

Most adults will scan green. The point of screening is to find the small number who are silently progressing, while there is still time to act. The platform is designed for routine baseline screening, not crisis diagnosis. Annual scans establish each patient’s individual trajectory and identify subclinical signals years or decades before symptoms emerge.

The Screening Pathway for Adults Age 50 to 65. Five sequential steps from baseline screening through intervention, with annual follow-up tracking NBSI and Trajectory Velocity Score over time.

The Complete Clinical Workflow. A six-stage continuous care pathway from identification through ongoing intervention and monitoring.

Section Nine

For Those With a Family History, the Case Is Sharper

Routine screening matters most for the people whose lifetime risk is already elevated. A first-degree relative with Alzheimer’s roughly doubles the lifetime risk. Multiple affected relatives across multiple generations raise it further. The current standard of care offers these families a stark choice: wait for symptoms, or pursue genetic testing that quantifies risk but cannot tell anyone whether the disease is actually beginning, or how quickly.

The platform does not replace family history. It works alongside it. Family history identifies who should be screened earlier and more often. The platform measures what is happening in their tissue right now, and how fast it is moving. Risk stratification answers probability. Tissue-level measurement answers timing.

This work is also personal. The inventor’s family has carried Alzheimer’s across multiple generations of the paternal line. His grandmother, her siblings, and his father have all been affected. He is currently his father’s primary caregiver. The 15 to 20 year preclinical window discussed throughout this page is the window in which the field of medicine could have changed his family’s trajectory, had a platform like this existed. Every family living with this disease has been told there was nothing anyone could have done sooner. We do not believe that has to remain true.

Section Ten

From Disease-Modifying Hope to Measurable Outcome

Cognitive testing cannot detect treatment response in real time. Tissue-level monitoring can. The platform makes it possible to identify treatment responders and non-responders within months rather than years, enabling clinicians to optimize disease-modifying therapy decisions while there is still time to change the patient’s trajectory.

Treatment Response Monitoring. Two patients on the same therapy, with the platform identifying biological responders and non-responders at month six, before clinical change is measurable.

Section Eleven

What Alzheimer’s Costs America

Alzheimer’s is the most economically significant chronic disease facing the United States. Direct medical costs are projected at 409 billion dollars in 2026. Unpaid family caregiving accounts for another 446 billion dollars. By 2050, the total annual burden is projected to reach 1 trillion dollars.

The economic case for pre-symptomatic screening is not a future hope. It is a present necessity.

The 409 Billion Question. The 2026 economic burden of Alzheimer's in America, including direct care, unpaid caregiving hours, and projected total cost by 2050.

Section Twelve

45 Percent of Cases Are Potentially Preventable

The 2024 Lancet Commission found that up to 45 percent of dementia cases worldwide are potentially preventable by addressing 14 modifiable risk factors across the life course. The platform’s pre-symptomatic detection window aligns with the period when most of those risk factors can still be modified.

Detection alone is not prevention. Risk modification alone is not enough. The combination, supported by tissue-level monitoring, is the most powerful pathway medicine has to offer for Alzheimer’s right now.

The 45 Percent Opportunity. The 14 modifiable Lancet Commission risk factors mapped across early life, midlife, and late life, with the platform-enabled pre-symptomatic detection window spanning ages 50 to 70.

Section Thirteen

What 15 Years Could Mean

This is the story of millions of American families. It is also the story of the future we believe medicine can build.

The same patient. The same 25 years. Two completely different lives, depending only on when we knew.

Two Timelines, Same Person, Same 25 Years. Standard-of-care timeline shown above, platform-enabled future shown below. What changed is when we knew. The 15 years matter.